SPECTROMETRY MARKET ANALYSIS

Spectrometry Market, By Product Type (Atomic Spectroscopy, (Atomic Absorption Spectroscopy, X- Ray Diffraction, Implantable, X-Ray Fluorescence, Inductively Coupled Plasma, Ark Spark, Elemental Analyzers, and ICP-MS), Mass Spectroscopy, (TANDEM LC/MS, Liquid Chromatography, Gas Chromatography, MALDI – TOF, Fourier Transform, and Single Quadrupole) and Molecular Spectroscopy (NMR, UV Visualization, Infrared, Color Measurement, and Near Infrared)), By End User (Biopharmaceutical industries, Research and Academic Institutes, and Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI3885
Pages :160
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Spectrometry Market: Key Developments

On January 5, 2023, Bruker Corporation, a U.S.-based company, announced the acquisition of ACQUIFER Imaging GmbH, a big data management solutions company, for bioimaging and high-content microscopy. This acquisition added on-site processing, secure storage, and networking technology to complement Bruker Corporation’s advanced fluorescence microscopy products, such as light plates and ultra-resolution microscopy products, that produce high information content.

On October 20, 2022 Analytikjena, a Germany-based company, explained how to analyze single nanoparticles and cells using fast time-resolved ICP-MS. Single-particle inductively coupled plasma mass spectrometry (spICP-MS) has been one of the main measurement methods for evaluating the chemical purity, consumer safety, and environmental safety of substances containing nanoparticles. Recent advancements in sampling systems, detection rates, and data processing strategies have paved the way for many new applications in this field.

On September 9, 2020, Bruker Corporation, a U.S. based company, published an article that said the Bead Assisted Mass Spectrometry assay platform is an approach for developing targeted proteomic assays of almost any protein target for which a specific affinity reagent (i.e., antibody or Affimer) is available. This approach utilizes multiplex immuno-affinity capture [2, 3]. Outstandingly, this assay uses an Affimer with S1 glycoprotein specificity instead of a monoclonal antibody for affinity capture.

On May 1, 2020, Avacta Group plc, a developer of Affimer biotherapeutics and reagents, announced that it entered into a collaboration with Adeptrix to develop a high throughput COVID-19 antigen test using Adeptrix’s proprietary bead-assisted mass spectrometr platform.